[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 7603
81. Coleman P, Barnard NA: Congenital hypertrophy of the retinal pigment epithelium: prevalence and ocular features in the optometric population. Ophthalmic Physiol Opt; 2007 Nov;27(6):547-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The progression of the condition could not be accurately described without follow-up.
  • No evidence was found to suggest a relationship between true CHRPE and familial adenomatous polyposis coli, Gardner's or Turcot's syndromes.
  • [MeSH-minor] Adenomatous Polyposis Coli / complications. Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Gardner Syndrome / complications. Humans. Hypertrophy / complications. Hypertrophy / congenital. Hypertrophy / pathology. Infant. Male. Middle Aged. Prevalence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956359.001).
  • [ISSN] 0275-5408
  • [Journal-full-title] Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)
  • [ISO-abbreviation] Ophthalmic Physiol Opt
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Lindqvist P, Olofsson BO, Backman C, Suhr O, Waldenström A: Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy. Eur J Echocardiogr; 2006 Jan;7(1):22-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy.
  • BACKGROUND: Familial amyloidotic polyneuropathy (FAP) is a hereditary systemic amyloidosis with cardiac involvement.
  • As early identification of the cardiac involvement is of major clinical interest we performed this study to test the hypothesis that tissue Doppler imaging (TDI) and strain imaging (SI) might disclose cardiac involvement in patients with early stages of FAP.
  • METHODS: Twenty-two patients with FAP and 36 healthy controls were studied.
  • CONCLUSIONS: This is the first clinical study using TDI and strain in patients with FAP showing functional abnormalities before any morphological echocardiographic abnormalities were present.
  • Both the left and right heart functions are involved and the disease should therefore be regarded as biventricular.
  • [MeSH-major] Amyloid Neuropathies, Familial / ultrasonography. Echocardiography, Doppler, Pulsed. Heart Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869906.001).
  • [ISSN] 1525-2167
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


83. Grubben MJ, van den Braak CC, Nagengast FM, Peters WH: Low colonic glutathione detoxification capacity in patients at risk for colon cancer. Eur J Clin Invest; 2006 Mar;36(3):188-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low colonic glutathione detoxification capacity in patients at risk for colon cancer.
  • BACKGROUND: Colon carcinogenesis is a multifactorial process influenced by hereditary as well as environmental factors.
  • The glutathione/glutathione S-transferase detoxification system in the colon is important for protection against carcinogens.
  • We investigated the levels of glutathione/glutathione S-transferase in normal colon mucosa of patients with colorectal cancer and in patients at high risk for colorectal cancer compared with those in healthy controls.
  • Normal colon tissue of patients with colon adenoma (n = 64), colorectal cancer (n = 37), familial adenomatous polyposis (FAP; n = 19), hereditary non-polyposis colorectal cancer families with (HNPCC+Ad; n = 34) or without (HNPCC-Ad; n = 33) adenoma was investigated.
  • RESULTS: Glutathione levels were significantly lower in the normal colon mucosa of patients with cancer, FAP, HNPCC-Ad or HNPCC+Ad compared with adenoma patients or healthy controls.
  • Glutathione S-transferase enzyme activity in the distal colon was significantly lower in patients with cancer or FAP compared with the adenoma patients or healthy controls, whereas values in carcinoma patients were significantly lower compared with both the HNPCC-Ad and HNPCC+Ad groups.
  • This low glutathione detoxification capacity might contribute to the colon cancer risk.
  • [MeSH-major] Colon / chemistry. Colorectal Neoplasms / chemistry. Glutathione / analysis
  • [MeSH-minor] Adenoma / chemistry. Adenoma / enzymology. Adenomatous Polyposis Coli / chemistry. Adenomatous Polyposis Coli / enzymology. Adult. Colonic Neoplasms / chemistry. Colonic Neoplasms / enzymology. Colorectal Neoplasms, Hereditary Nonpolyposis / chemistry. Colorectal Neoplasms, Hereditary Nonpolyposis / enzymology. Female. Glutathione Transferase / metabolism. Humans. Intestinal Mucosa / chemistry. Intestinal Mucosa / enzymology. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506964.001).
  • [ISSN] 0014-2972
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.5.1.18 / Glutathione Transferase; GAN16C9B8O / Glutathione
  •  go-up   go-down


8
Advertisement
4. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer; 2008;8:82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The meta-analysis revealed a significant survival benefit for GEM+X with a pooled hazard ratio (HR) of 0.91 (95% CI: 0.85 - 0.97, p = 0.004).
  • The analysis of platinum-based combinations indicated a HR of 0.85 (95% CI: 0.76 - 0.96, p = 0.010), while for fluoropyrimidine-based combinations the HR was 0.90 (95% CI: 0.81 - 0.99, p = 0.030).
  • This analysis indicated that patients with a good PS had a marked survival benefit when receiving combination chemotherapy (HR = 0.76; 95% CI: 0.67 - 0.87; p < 0.0001).
  • By contrast, application of combination chemotherapy to patients with an initially poor PS appeared to be ineffective (HR = 1.08; 95% CI: 0.90 - 1.29, p = 0.40).

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1261-8 [10189130.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1639-45 [16087696.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD002093 [16855985.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3946-52 [16921047.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):587-92 [16909140.001]
  • [Cites] World J Gastroenterol. 2006 Nov 21;12(43):6973-81 [17109519.001]
  • [Cites] World J Gastroenterol. 2007 Jan 14;13(2):224-7 [17226900.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2607-15 [17577041.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):525-33 [17577216.001]
  • [Cites] Drugs Aging. 2007;24(10):865-79 [17896834.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):902-10 [11920457.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):161-7 [12107836.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):97-104 [12488300.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3296-302 [12947065.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1430-8 [15084616.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3776-83 [15365074.001]
  • [Cites] Control Clin Trials. 1996 Feb;17(1):1-12 [8721797.001]
  • [Cites] Lancet. 1997 Feb 15;349(9050):485-9 [9040589.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Stat Med. 1998 Dec 30;17(24):2815-34 [9921604.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):185-9 [15986036.001]
  • (PMID = 18373843.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoacridines; 0 / Antimetabolites, Antineoplastic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 316-83-6 / fluoroquinacrine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2292732
  •  go-up   go-down


85. Miller JJ, Summers MK, Hansen DV, Nachury MV, Lehman NL, Loktev A, Jackson PK: Emi1 stably binds and inhibits the anaphase-promoting complex/cyclosome as a pseudosubstrate inhibitor. Genes Dev; 2006 Sep 01;20(17):2410-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The periodic destruction of mitotic cyclins is triggered by the activation of the anaphase-promoting complex/cyclosome (APC/C) in mitosis.
  • Although the ability of the APC/C to recognize destruction box (D-box) substrates oscillates throughout the cell cycle, the mechanism regulating APC/C binding to D-box substrates remains unclear.
  • Here, we show that the APC/C inhibitor Emi1 tightly binds both the APC/C and its Cdh1 activator, binds to the D-box receptor site on the APC/C(Cdh1), and competes with APC/C substrates for D-box binding.
  • Emi1 itself contains a conserved C-terminal D-box, which provides APC/C-binding affinity, and a conserved zinc-binding region (ZBR), which antagonizes APC/C E3 ligase activity independent of tight APC binding.
  • Mutation of the ZBR converts Emi1 into a D-box-dependent APC/C substrate.
  • The identification of a direct Emi1-APC/C complex further explains how Emi1 functions as a stabilizing factor for cyclin accumulation and the need to destroy Emi1 for APC/C activation in mitosis.
  • The combination of a degron/E3 recognition site and an anti-ligase function in Emi1 suggests a general model for how E3 substrates evolve to become pseudosubstrate inhibitors.
  • [MeSH-major] Cell Cycle Proteins / physiology. Enzyme Inhibitors. F-Box Proteins / physiology. Ubiquitin-Protein Ligase Complexes / antagonists & inhibitors. Ubiquitin-Protein Ligase Complexes / metabolism
  • [MeSH-minor] Amino Acid Motifs. Anaphase-Promoting Complex-Cyclosome. Binding, Competitive. Cadherins / metabolism. Cadherins / physiology. Cell Nucleus / enzymology. Cell Nucleus / metabolism. Conserved Sequence. HeLa Cells. Humans. Interphase / physiology. Protein Binding. Substrate Specificity

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Mar 15;14(6):655-65 [10733526.001]
  • [Cites] Mol Cell. 2005 May 27;18(5):543-53 [15916961.001]
  • [Cites] J Cell Biol. 2001 Apr 2;153(1):121-36 [11285279.001]
  • [Cites] J Cell Biol. 2001 Apr 2;153(1):137-48 [11285280.001]
  • [Cites] Cell. 2001 Jun 1;105(5):645-55 [11389834.001]
  • [Cites] Curr Biol. 2001 Apr 3;11(7):508-13 [11413001.001]
  • [Cites] Curr Biol. 2001 Sep 4;11(17):1347-52 [11553328.001]
  • [Cites] Genes Dev. 2001 Sep 15;15(18):2396-407 [11562349.001]
  • [Cites] Development. 2001 Oct;128(19):3795-807 [11585805.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3278-85 [11751633.001]
  • [Cites] Genes Dev. 2002 Feb 15;16(4):439-51 [11850407.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):358-66 [11988738.001]
  • [Cites] Genes Dev. 2002 Sep 1;16(17):2179-206 [12208841.001]
  • [Cites] EMBO J. 2003 Feb 17;22(4):786-96 [12574115.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):799-812 [12791266.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):813-26 [12791267.001]
  • [Cites] Mol Cell. 2004 Jan 16;13(1):137-47 [14731401.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):129-37 [14743218.001]
  • [Cites] Nature. 2004 Mar 11;428(6979):190-3 [15014502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 25;101(21):7937-42 [15148369.001]
  • [Cites] Dev Cell. 2004 Jul;7(1):45-60 [15239953.001]
  • [Cites] Trends Cell Biol. 2004 Jul;14(7):331-4 [15246424.001]
  • [Cites] Nature. 1991 Jan 10;349(6305):132-8 [1846030.001]
  • [Cites] Cell. 1991 Aug 9;66(3):507-17 [1651171.001]
  • [Cites] Cell. 1991 Aug 9;66(3):519-31 [1651172.001]
  • [Cites] Nature. 1996 Jul 25;382(6589):325-31 [8684460.001]
  • [Cites] Mol Biol Cell. 1996 Sep;7(9):1343-57 [8885231.001]
  • [Cites] Cell. 1997 Aug 22;90(4):683-93 [9288748.001]
  • [Cites] Science. 1997 Oct 17;278(5337):460-3 [9334304.001]
  • [Cites] Science. 1998 Feb 20;279(5354):1219-22 [9469815.001]
  • [Cites] Science. 1998 Nov 27;282(5394):1721-4 [9831566.001]
  • [Cites] Protein Sci. 1999 Jul;8(7):1557-61 [10422847.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):637-51 [15525526.001]
  • [Cites] Mol Biol Cell. 2004 Dec;15(12):5623-34 [15469984.001]
  • [Cites] Curr Biol. 2005 Jan 11;15(1):11-8 [15649358.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):314-25 [15678131.001]
  • [Cites] Genes Dev. 2005 Feb 15;19(4):502-13 [15713843.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4318-23 [15753281.001]
  • [Cites] Cell. 2005 Mar 25;120(6):739-46 [15797376.001]
  • [Cites] Mol Cell. 2005 May 27;18(5):533-42 [15916960.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(13):4614-25 [10848588.001]
  • (PMID = 16921029.001).
  • [ISSN] 0890-9369
  • [Journal-full-title] Genes & development
  • [ISO-abbreviation] Genes Dev.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM054811; United States / NIGMS NIH HHS / GM / T32 GM007365; United States / NCI NIH HHS / CA / T32 CA009151; United States / NIGMS NIH HHS / GM / R01 GM060439; United States / NIGMS NIH HHS / GM / GM07365; United States / NINDS NIH HHS / NS / K08 NS045077; United States / NCI NIH HHS / CA / CA09151; United States / NIGMS NIH HHS / GM / R01 GM54811; United States / NIGMS NIH HHS / GM / R01 GM60439
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins; 0 / Cell Cycle Proteins; 0 / Enzyme Inhibitors; 0 / F-Box Proteins; 0 / FBXO5 protein, human; EC 2.3.2.23 / Ubiquitin-Protein Ligase Complexes; EC 2.3.2.27 / Anaphase-Promoting Complex-Cyclosome
  • [Other-IDs] NLM/ PMC1560415
  •  go-up   go-down


86. Cohen Z, Senagore AJ, Dayton MT, Koruda MJ, Beck DE, Wolff BG, Fleshner PR, Thirlby RC, Ludwig KA, Larach SW, Weiss EG, Bauer JJ, Holmdahl L: Prevention of postoperative abdominal adhesions by a novel, glycerol/sodium hyaluronate/carboxymethylcellulose-based bioresorbable membrane: a prospective, randomized, evaluator-blinded multicenter study. Dis Colon Rectum; 2005 Jun;48(6):1130-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Postoperative abdominal adhesions are associated with significant morbidity and mortality, placing a substantial burden on healthcare systems worldwide.
  • Development of a bioresorbable membrane containing up to 23 percent glycerol and chemically modified sodium hyaluronate/carboxymethylcellulose offers ease of handling and has been shown to provide significant postoperative adhesion prevention in animals.
  • METHODS: Twelve centers enrolled 120 patients with ulcerative colitis or familial polyposis who were scheduled for a restorative proctocolectomy and ileal pouch-anal anastomosis with diverting loop ileostomy.
  • Safety profiles for the treatment and no treatment control groups were similar with the exception of more infection complications associated with glycerol hyaluronate/carboxymethylcellulose use.
  • Animal models did not predict these complications.

  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLYCERIN .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868230.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Biocompatible Materials; 0 / Membranes, Artificial; 9004-32-4 / Carboxymethylcellulose Sodium; 9004-61-9 / Hyaluronic Acid; PDC6A3C0OX / Glycerol
  •  go-up   go-down


87. Abbas O, Richards JE, Mahalingam M: Fibroblast-activation protein: a single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma. Mod Pathol; 2010 Nov;23(11):1535-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibroblast-activation protein: a single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma.
  • Fibroblast-activation protein, a type II membrane-bound glycoprotein belonging to the serine protease family, is expressed in the granulation tissue of healing wounds.
  • More recently, it has been identified as a marker of reactive tumor stromal fibroblasts, as it is reportedly selectively expressed in peritumoral stromal fibroblasts of multiple epithelial cancers including cutaneous malignancies such as basal cell carcinoma.
  • Given this, we sought to ascertain the use of fibroblast-activation protein in distinguishing morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma.
  • Immunohistochemical staining for fibroblast-activation protein was performed on desmoplastic trichoepithelioma (n=25) and morpheaform/infiltrative basal cell carcinoma (n=25), with the control group comprising scars from reexcision specimens (n=10).
  • As expected, fibroblast-activation protein expression was observed in stromal fibroblasts of all control cases (10 of 10, 100%).
  • Of interest, fibroblast-activation protein expression was observed in peritumoral fibroblasts of all cases of morpheaform/infiltrative basal cell carcinoma (25 of 25, 100%) but not in any cases of desmoplastic trichoepithelioma (0 of 25, 0%).
  • A gradient of fibroblast-activation protein expression was observed in morpheaform/infiltrative basal cell carcinoma with more intense expression noted in fibroblasts abutting the tumor cells, a less intense expression in the distal peritumoral stromal portion, and minimal to loss of expression in adjacent normal tissue.
  • In summary, findings from this study underscore the use of fibroblast-activation protein as a histologic adjunct in confidently differentiating morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Fibroblasts / enzymology. Gelatinases / analysis. Membrane Proteins / analysis. Serine Endopeptidases / analysis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Boston. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Young Adult


88. Elligers KT, Davies M, Sanchis D, Ferencz T, Saif MW: Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting? JOP; 2008;9(2):197-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In an event of a platinum hypersensitivity reaction, the particular platinum salt is likely discontinued.
  • The patient has tolerated multiple additional cycles with further decrease in tumor size and tumor markers.


89. Kashyap MK, Marimuthu A, Kishore CJ, Peri S, Keerthikumar S, Prasad TS, Mahmood R, Rao S, Ranganathan P, Sanjeeviah RC, Vijayakumar M, Kumar KV, Montgomery EA, Kumar RV, Pandey A: Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers. Cancer Biol Ther; 2009 Jan;8(1):36-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esophageal squamous cell carcinoma (ESCC) is predominant type of esophageal cancers worldwide comprising almost 95% of cases.
  • In spite of its higher prevalence, ESCC has not been studied as intensively as esophageal adenocarcinoma.
  • In order to identify molecules as candidates for early diagnosis and/or as therapeutic targets, we analyzed the mRNA expression profiles of 20 cases of ESCC using whole genome DNA microarrays.
  • We validated two molecules that were not previously reported to be overexpressed in ESCC, oral cancer overexpressed 2 (ORAOV2) and fibroblast activation protein (FAP), by immunohistochemical labeling of tissue microarrays and archival tissue sections and found that they were overexpressed in 98% (116/118) and 68% (79/116) of cases, respectively.
  • Overall, using this approach we have identified a number of promising novel candidates that can be validated further for their potential to serve as biomarkers for ESCC.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. Esophageal Neoplasms / genetics. Genome-Wide Association Study. Neoplasm Proteins / genetics. RNA, Messenger / genetics
  • [MeSH-minor] Antigens, Neoplasm / genetics. DNA, Neoplasm / genetics. Gelatinases. Gene Expression Regulation, Neoplastic. Humans. Membrane Proteins. Oligonucleotide Array Sequence Analysis. RNA, Neoplasm / genetics. Serine Endopeptidases / genetics. Up-Regulation

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981721.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


90. Mátrai Z, Papp J, Polgár C, Hitre E, Köves I, Oláh E, Andi J, Kiss A, Vámosi Nagy I, Tóth L, Orosz Z: [Long-term experience with therapy of a female patient with Gardner's syndrome, first presenting with extra-abdominal desmoid tumor, and review of the literature]. Magy Seb; 2009 Apr;62(2):75-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term experience with therapy of a female patient with Gardner's syndrome, first presenting with extra-abdominal desmoid tumor, and review of the literature].
  • Gardner's syndrome is a clinical subgroup of familial adenomatous polyposis, an autosomal dominant disease.
  • It is characterized by gastrointestinal polyps and extra-intestinal manifestations including multiple osteomas, skin and soft tissue tumours.
  • Aggressive desmoid tumours can be very difficult to manage in patients with Gardner's syndrome.
  • We present a case of a 17-year-old female who presented with an aggressive desmoid tumor arising of the lumbar area as part of her Gardner's syndrome.
  • We conclude that desmoid tumors can precede gastrointestinal manifestations of familial adenomatous polyposis or Gardner's syndrome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fibromatosis, Aggressive / diagnosis. Fibromatosis, Aggressive / genetics. Gardner Syndrome / diagnosis. Gardner Syndrome / genetics. Genes, APC

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19386568.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 30
  •  go-up   go-down


91. Norhana MN, Azman MN, Poole SE, Deeth HC, Dykes GA: Effects of bilimbi (Averrhoa bilimbi L.) and tamarind (Tamarindus indica L.) juice on Listeria monocytogenes Scott A and Salmonella Typhimurium ATCC 14028 and the sensory properties of raw shrimps. Int J Food Microbiol; 2009 Nov 30;136(1):88-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of bilimbi (Averrhoa bilimbi L.) and tamarind (Tamarindus indica L.) juice on Listeria monocytogenes Scott A and Salmonella Typhimurium ATCC 14028 and the sensory properties of raw shrimps.
  • The potential of using juice of bilimbi (Averrhoa bilimbi L.) and tamarind (Tamarindus indica L.) to reduce Listeria monocytogenes Scott A and Salmonella Typhimurium ATCC 14028 populations on raw shrimps after washing and during storage (4 degrees C) was investigated.
  • The uninoculated raw shrimps and those inoculated with approximately 9 log cfu/ml of L. monocytogenes Scott A and S.
  • Naturally occurring aerobic bacteria (APC), L. monocytogenes Scott A and S.
  • Compared to SDW, bilimbi and tamarind juice significantly (p<0.05) reduced APC (0.40-0.70 log cfu/g), L. monocytogenes Scott A (0.84-1.58 log cfu/g) and S.
  • There was a significant difference (p<0.05) in bacterial reduction between the dipping (0.40-0.41 log for APC; 0.84 for L. monocytogenes Scott A and 1.03-1.09 log for S.
  • Typhimurium ATCC 14028) and rubbing (0.68-0.70 log for APC; 1.34-1.58 for L. monocytogenes Scott A and 1.67-2.00 log for S.
  • Regardless of washing treatments or methods, populations of S.
  • Typhimurium ATCC 14028 decreased slightly (5.10-6.29 log cfu/g on day 7 of storage) while populations of L. monocytogenes Scott A (8.74-9.20 log cfu/g) and APC (8.68-8.92 log cfu/g) increased significantly during refrigerated storage.
  • The control, bilimbi or tamarind-washed shrimps did not differ in sensory panellist acceptability (p>0.05) throughout the storage except for odour (p<0.05) attributes at 0 day when acidic or lemony smell was noticed in bilimbi- and tamarind-washed shrimps and not in control shrimps.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19818521.001).
  • [ISSN] 1879-3460
  • [Journal-full-title] International journal of food microbiology
  • [ISO-abbreviation] Int. J. Food Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Disinfectants; 0 / Plant Extracts
  •  go-up   go-down


92. Labori KJ, Hjermstad MJ, Wester T, Buanes T, Loge JH: Symptom profiles and palliative care in advanced pancreatic cancer: a prospective study. Support Care Cancer; 2006 Nov;14(11):1126-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To describe prospectively the prevalence and severity of disease-related symptoms, quality of life (QOL) and need for palliative care in patients with advanced pancreatic cancer.
  • RESULTS: Of the 22 women and 29 men (mean age, 62 years), 20 had locally unresectable cancer, 19 had metastatic disease, and 12 had recurrent disease after curative resection.
  • A multidisciplinary approach is necessary for the best palliation of symptoms at the time of diagnosis and during follow-up.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Norway / epidemiology. Prevalence. Prospective Studies. Quality of Life. Severity of Illness Index. Surveys and Questionnaires. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Ann Surg. 1990 Aug;212(2):132-9 [1695834.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1188-96 [9508207.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):471-7 [15672431.001]
  • [Cites] Endoscopy. 2004 Jun;36(6):543-50 [15202052.001]
  • [Cites] Palliat Med. 1998 Mar;12(2):75-82 [9616443.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):850-6 [3802043.001]
  • [Cites] Br J Cancer. 2003 Aug;89 Suppl 1:S107-10 [12915911.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):322-8; discussion 328-30 [10493479.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jul;13(3):491-503, ix [15236731.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):894-902; discussion 902-5 [14631226.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4077-82 [11911295.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Eur J Cancer. 1999 Jun;35(6):939-41 [10533475.001]
  • [Cites] J Palliat Care. 1991 Summer;7(2):6-9 [1714502.001]
  • [Cites] J Chronic Dis. 1987;40(6):545-56 [3597658.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):971-5 [11038033.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1998-2004 [10430384.001]
  • [Cites] JAMA. 2004 Mar 3;291(9):1092-9 [14996778.001]
  • [Cites] J Am Coll Surg. 1999 Jun;188(6):658-66; discussion 666-9 [10359359.001]
  • [Cites] Palliat Med. 1999 Jul;13(4):299-310 [10659099.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):549-57 [11520088.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):3-27 [15221985.001]
  • [Cites] J Pain Symptom Manage. 2001 Aug;22(2):649-56 [11495711.001]
  • [Cites] J Chronic Dis. 1986;39(1):47-62 [2418050.001]
  • [Cites] CA Cancer J Clin. 2002 Mar-Apr;52(2):72-91 [11929007.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • (PMID = 16601947.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


93. Lage A: On the cross-fertilization between biotechnology and immunology: current situation in Cuba. Vaccine; 2006 Apr 12;24 Suppl 2:S2-3-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Current understanding of antigen presentation and the maturation of dendritic cells has opened the way for a more rational design of new adjuvants, intended not only to deliver the antigen to antigen presenting cells (APC) and to induce APC maturation, but also to direct lymphocyte differentiation towards either Th1 or Th2 phenotypes, and to deal with disease-induced immunodepression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16823906.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Vaccines
  • [Number-of-references] 10
  •  go-up   go-down


94. Markova M, Koratkar RA, Silverman KA, Sollars VE, MacPhee-Pellini M, Walters R, Palazzo JP, Buchberg AM, Siracusa LD, Farber SA: Diversity in secreted PLA2-IIA activity among inbred mouse strains that are resistant or susceptible to Apc Min/+ tumorigenesis. Oncogene; 2005 Sep 22;24(42):6450-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diversity in secreted PLA2-IIA activity among inbred mouse strains that are resistant or susceptible to Apc Min/+ tumorigenesis.
  • The secreted phospholipase A2 type IIA (Pla2g2a) gene was previously identified as a modifier of intestinal adenoma multiplicity in Apc Min/+ mice.
  • To determine if intestinal secreted phospholipase A2 (sPLA2) activity was also attenuated in susceptible strains, we developed a sensitive assay to directly quantitate sPLA2 activity in the murine intestinal tract utilizing a fluorescent BODIPY-labeled phospholipid substrate.
  • Here, we report assay conditions that distinguish between secreted and cytosolic PLA2 enzyme activities in extracts of intestinal tissue.
  • The small intestine exhibited higher activity levels than the large intestine.
  • Consistent with predictions from the sPLA2-IIA gene sequence in inbred strains, we detected low levels of enzyme activity in inbred strains containing sPLA2-IIA mutations; these strains were also associated with greater numbers of intestinal polyps.
  • Additionally, the assay was able to distinguish differences in levels of sPLA2 activity between neoplasia-resistant strains, which were then shown by sequencing to carry variant wild-type sPLA2-IIA alleles.
  • Immunohistochemical analyses of intestinal tissues were consistent with sPLA2-IIA activity levels.
  • This approach enables further studies of the mechanisms of sPLA2 action influencing the development and tumorigenesis of the small intestine and colon in both mice and humans.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Genes, APC. Phospholipases A / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Boron Compounds. Group II Phospholipases A2. Immunohistochemistry. Intestinal Neoplasms / enzymology. Intestine, Large / enzymology. Intestine, Small / enzymology. Mice. Mice, Inbred Strains. Molecular Sequence Data. Molecular Weight. Phospholipases A2. Sequence Homology, Amino Acid. Species Specificity

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007193.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA72027; United States / NCI NIH HHS / CA / R01 CA89560; United States / NIDDK NIH HHS / DK / R01 DK060369
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene; 0 / Boron Compounds; EC 3.1.1.- / Phospholipases A; EC 3.1.1.4 / Group II Phospholipases A2; EC 3.1.1.4 / Phospholipases A2; EC 3.1.1.4 / Pla2g2a protein, mouse
  •  go-up   go-down


95. Lavergne SN, Wang H, Callan HE, Park BK, Naisbitt DJ: "Danger" conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells. J Pharmacol Exp Ther; 2009 Nov;331(2):372-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Danger" conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells.
  • Antigen-presenting cells (APC) are thought to play an important role in the pathogenesis of drug-induced immune reactions.
  • Various pathological factors can activate APC and therefore influence the immune equilibrium.
  • It is interesting that several diseases have been associated with an increased rate of drug allergy.
  • The aim of this project was to evaluate the impact of such "danger signals" on sulfamethoxazole (SMX) metabolism in human APC (peripheral blood mononuclear cells, Epstein-Barr virus-modified B lymphocytes, monocyte-derived dendritic cells, and two cell lines).
  • APC were incubated with SMX (100 microM-2 mM; 5 min-24 h), in the presence of pathological factors: bacterial endotoxins (lipopolysaccharide and staphylococcal enterotoxin B), flu viral proteins, cytokines [interleukin (IL)-1beta, IL-6, IL-10; tumor necrosis factor-alpha; interferon-gamma; and transforming growth factor-beta], inflammatory molecules (prostaglandin E2, human serum complement, and activated protein C), oxidants (buthionine sulfoximine and H(2)O(2)), and hyperthermia (37.5-39.5 degrees C).
  • SMX-protein adduct formation was time- and concentration-dependent for each cell type tested, in both physiological and danger conditions.
  • A danger environment significantly increased the formation of SMX-protein adducts and significantly shortened the delay for their detection.
  • Various enzyme inhibitors were associated with a significant decrease in SMX-adduct levels, with a pattern varying depending on the cell type and the culture conditions.
  • These results illustrate that danger signals enhance the formation of intracellular SMX-protein adducts in human APC.
  • These findings might be relevant to the increased frequency of drug allergy in certain disease states.

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. SULFAMETHOXAZOLE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunol Allergy Clin North Am. 2004 Aug;24(3):477-90, vii [15242722.001]
  • [Cites] Biochemistry. 2003 Aug 26;42(33):9906-14 [12924939.001]
  • [Cites] Lancet. 1989 Dec 2;2(8675):1294-8 [2574255.001]
  • [Cites] Mol Pharmacol. 1990 Nov;38(5):744-51 [2172779.001]
  • [Cites] Drug Metab Dispos. 1991 Sep-Oct;19(5):900-6 [1686233.001]
  • [Cites] Biochem Pharmacol. 1993 Mar 24;45(6):1277-82 [8466547.001]
  • [Cites] Oncol Res. 1993;5(1):11-8 [8396466.001]
  • [Cites] Xenobiotica. 1998 Jun;28(6):559-69 [9667079.001]
  • [Cites] J Paediatr Child Health. 1998 Aug;34(4):325-9 [9727171.001]
  • [Cites] Semin Immunol. 1998 Oct;10(5):399-415 [9840976.001]
  • [Cites] Free Radic Biol Med. 1999 Jan;26(1-2):232-8 [9890657.001]
  • [Cites] Br J Pharmacol. 1999 Mar;126(6):1393-407 [10217534.001]
  • [Cites] Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):358-61 [10224446.001]
  • [Cites] Chem Res Toxicol. 1999 Jun;12(6):488-500 [10368311.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):17982-7 [15604151.001]
  • [Cites] Biochem Pharmacol. 2005 Jul 15;70(2):275-86 [15894292.001]
  • [Cites] Cancer Immunol Immunother. 2006 Mar;55(3):292-8 [15864585.001]
  • [Cites] Drug Metab Dispos. 2006 Jan;34(1):16-8 [16214851.001]
  • [Cites] Toxicology. 2006 Feb 1;218(2-3):90-9 [16289751.001]
  • [Cites] J Support Oncol. 2006 Jan;4(1):9-16 [16444847.001]
  • [Cites] Toxicology. 2006 May 1;222(1-2):25-36 [16473451.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Oct;319(1):497-505 [16857727.001]
  • [Cites] J Leukoc Biol. 2006 Dec;80(6):1251-61 [16973890.001]
  • [Cites] Drug Metab Dispos. 2007 Apr;35(4):676-81 [17220235.001]
  • [Cites] J Immunol. 2007 May 1;178(9):5533-42 [17442935.001]
  • [Cites] Am J Clin Nutr. 2007 May;85(5):1335-43 [17490971.001]
  • [Cites] J Immunol. 2007 Nov 15;179(10):6456-67 [17982034.001]
  • [Cites] Mol Pharmacol. 2008 Jun;73(6):1769-75 [18334600.001]
  • [Cites] Curr Opin Chem Biol. 2008 Dec;12(6):746-54 [18804173.001]
  • [Cites] Chem Res Toxicol. 2009 May;22(5):937-48 [19358516.001]
  • [Cites] J Immunol. 2003 Sep 1;171(5):2262-9 [12928370.001]
  • [Cites] Curr Opin Immunol. 2001 Feb;13(1):114-9 [11154927.001]
  • [Cites] IUBMB Life. 2000 Oct-Nov;50(4-5):331-5 [11327328.001]
  • [Cites] Br J Pharmacol. 2001 May;133(2):295-305 [11350866.001]
  • [Cites] Biochem Pharmacol. 2001 Aug 15;62(4):457-9 [11448455.001]
  • [Cites] Mol Pharmacol. 2002 Sep;62(3):628-37 [12181439.001]
  • [Cites] Chem Biol Interact. 2002 Nov 10;142(1-2):155-73 [12399161.001]
  • [Cites] Curr Opin Immunol. 2002 Dec;14(6):765-70 [12413527.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Jul;306(1):229-37 [12676884.001]
  • [Cites] Am J Clin Nutr. 2004 Aug;80(2):374-84 [15277158.001]
  • (PMID = 19666748.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / / 078598/Z/05/Z; United Kingdom / Medical Research Council / / G0700654
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Cyclohexanones; 0 / Cytokines; 0 / Endotoxins; 0 / Enzyme Inhibitors; 0 / Inflammation Mediators; 0 / Oxidants; 0 / Viral Proteins; B2B5DSX2FC / dimedone; JE42381TNV / Sulfamethoxazole
  • [Other-IDs] NLM/ PMC2775259
  •  go-up   go-down


96. Koom WS, Seong J, Kim YB, Pyun HO, Song SY: CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys; 2009 Mar 15;73(4):1148-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median survival time (MST) was 12 months (range, 4-48 months), and 1-year survival rate was 44%.
  • In addition, patients with multiple unfavorable CA 19-9 levels had significantly worse outcomes than those without.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760544.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


97. Shen G, Khor TO, Hu R, Yu S, Nair S, Ho CT, Reddy BS, Huang MT, Newmark HL, Kong AN: Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse. Cancer Res; 2007 Oct 15;67(20):9937-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse.
  • Male ApcMin/+ mice (12 per group) at age of 5 weeks were given control AIN-76A diet, diets containing 600 ppm SFN and 1.0% DBM, or a combination of 300 ppm SFN and 0.5% DBM for 10 weeks.
  • Dietary administrations of SFN and DBM alone or in combination significantly inhibited the development of intestinal adenomas by 48% (P=0.002), 50% (P=0.001), and 57% (P<0.001), respectively.
  • Dietary administration of 600 ppm SFN and 1.0% DBM also reduced colon tumor numbers by 80% (P=0.016) and 60% (P=0.103), respectively, whereas the combination of SFN and DBM treatment blocked the colon tumor development (P=0.002).
  • Both SFN and DBM treatments resulted in decreased levels of prostaglandin E2 or leukotriene B4 in intestinal polyps or apparently normal mucosa.
  • [MeSH-major] Adenomatous Polyposis Coli / prevention & control. Anticarcinogenic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Chalcones / pharmacology. Thiocyanates / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Arachidonic Acid / metabolism. Body Weight / drug effects. Cell Cycle Proteins / biosynthesis. Diet. Gene Expression Profiling. Intestine, Small / metabolism. Isothiocyanates. Male. Mice. Mitogen-Activated Protein Kinases / metabolism. Phosphorylation / drug effects. Polymerase Chain Reaction. Proto-Oncogene Proteins c-akt / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942926.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-092515; United States / NCI NIH HHS / CA / R01 CA-073674-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Cell Cycle Proteins; 0 / Chalcones; 0 / Isothiocyanates; 0 / Thiocyanates; 27YG812J1I / Arachidonic Acid; 4478-93-7 / sulforafan; ANS7ME8OKC / dibenzoylmethane; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


98. Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz JF, Moussy A, Kinet JP, Hermine O, Rougier P, Raymond E: Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol; 2010 Jul;66(2):395-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secondary endpoints included overall survival (OS), as well as, subgroup analyses according to baseline disease, and performance status.
  • RESULTS: Overall median TTP was 6.4 months (95% CI [2.7-11.7]); 8.3 and 2.7 months, respectively, for locally advanced and metastatic patients; 6.4 and 0.8 months, respectively, for patients with KPS [80-100] or KPS [70].
  • Median OS was 7.1 months (95% CI [4.8-17.0]); 8.4 and 6.8 months for locally advanced or metastatic patients, respectively; 8.0 and 4.4 months in patients with KPS [80-100] or KPS [70], respectively.
  • CONCLUSIONS: The efficacy and safety of masitinib combined with gemcitabine are encouraging, with extended survival and median TTP that support initiation of a phase 3 trial.
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Dose-Response Relationship, Drug. Endpoint Determination. Female. Hematologic Diseases / chemically induced. Hematologic Diseases / epidemiology. Humans. Male. Middle Aged. Survival Analysis. Thiazoles / administration & dosage

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20364428.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Thiazoles; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; M59NC4E26P / masitinib
  •  go-up   go-down


99. Terdiman JP: MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story. Gastroenterology; 2009 Dec;137(6):1883-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. DNA Glycosylases / genetics
  • [MeSH-minor] Breast Neoplasms / epidemiology. Breast Neoplasms / genetics. Endoscopy. Female. Gastrointestinal Neoplasms / epidemiology. Gastrointestinal Neoplasms / genetics. Genetic Predisposition to Disease. Humans. Incidence. Male. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / genetics. Phenotype. Risk Assessment. Risk Factors. Sebaceous Gland Neoplasms / epidemiology. Sebaceous Gland Neoplasms / genetics. Skin Neoplasms / epidemiology. Skin Neoplasms / genetics. Urinary Bladder Neoplasms / epidemiology. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - MYH-associated polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Gastroenterology. 2009 Dec;137(6):1976-85.e1-10 [19732775.001]
  • (PMID = 19879216.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase
  •  go-up   go-down


100. Lang LH: Embryo testing for FAP gets approved in UK. Gastroenterology; 2005 Jan;128(1):4-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryo testing for FAP gets approved in UK.
  • [MeSH-major] Adenomatous Polyposis Coli / diagnosis. Preimplantation Diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15633112.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down






Advertisement